ProCE Banner Activity

What Does New Data From IAS 2021 on Opportunistic Infections in Patients With HIV Mean for Latin America?

Clinical Thought
My insights from Latin America on the results of the AMBITION-cm trial using single, high dose of liposomal Amphotericin B vs standard therapy for cryptococcal meningitis.

Released: August 20, 2021

Expiration: August 19, 2022

No longer available for credit.

Share

Faculty

Pedro Cahn

Pedro Cahn, MD, PhD

Scientific Director, Fundación Huésped
Former Professor of Infectious Disease
University of Buenos Aires
Past President
International AIDS Society
Buenos Aires, Argentina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

IAS 2021

ProCE Banner

Faculty Disclosure

Primary Author

Pedro Cahn, MD, PhD

Scientific Director, Fundación Huésped
Former Professor of Infectious Disease
University of Buenos Aires
Past President
International AIDS Society
Buenos Aires, Argentina

Pedro Cahn, MD, PhD, has disclosed that he has received funds for research support and consulting fees from Merck and ViiV and fees for non-CME/CE services from Gilead Sciences, Merck, and ViiV.